# Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)

> **NCT07500285** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization** · enrollment: 10 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Metastatic Lung Carcinoma

## Interventions

- **DRUG:** Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor (Y-90 FAPI)

## Key facts

- **NCT ID:** NCT07500285
- **Lead sponsor:** Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2027-06-15
- **Final completion:** 2027-11-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07500285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07500285, "Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07500285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*